Interventions to improve osteoporosis medication adherence and persistence: A systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group

Osteoporosis International

Volumn 24, Issue 12, 2013, Pages 2907-2918

  Hiligsmann, M ^a   Salas, M ^b,c,d   Hughes, D A ^e   Manias, E ^f   Gwadry Sridhar, F H ^g,h   Linck, P ^e   Cowell, W ⁱ  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c PFIZER INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e BANGOR UNIVERSITY   (United Kingdom)

^f THE UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

ⁱ PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Adherence; Intervention; Osteoporosis; Persistence

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; CLODRONIC ACID; COLECALCIFEROL; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

DOSAGE SCHEDULE COMPARISON; ELECTRONIC PRESCRIBING; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; MEDICATION COMPLIANCE; META ANALYSIS; OSTEOPENIA; PATIENT CARE; PATIENT EDUCATION; PHARMACEUTICAL CARE; PHARMACIST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TELECONSULTATION; TELEHEALTH;

BONE DENSITY CONSERVATION AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; OSTEOPOROSIS; PATIENT EDUCATION AS TOPIC; RESEARCH DESIGN;

EID: 84890428807     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2364-z     Document Type: Review

References (39)

1. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928
2. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943-1951
3. Rabenda V, Hiligsmann M, Reginster J-Y (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10:2303-2315
4. Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811-818
5. Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022
6. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RMC, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3-S13
7. Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170-177
8. Landfeldt E, Lundkvist J, Strom O (2011) The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48:380-388
9. Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15:604-612
10. Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394-401
11. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202-210
12. McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288:2868-2879
13. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev CD000011
14. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271
15. Gleeson T, Iversen MD, Avorn J et al (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127-2134
16. Verhagen AP, de Vet HC, de Bie RA et al (1998) The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51:1235-1241
17. Blalock SJ, DeVellis BM, Patterson CC, Campbell MK, Orenstein DR, Dooley MA (2002) Effects of an osteoporosis prevention program incorporating tailored educational materials. Am J Health Promot 16:146-156
18. Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117-1123
19. Cook PF, Emiliozzi S, McCabe MM (2007) Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am J Med Qual 22:445-456
20. Delmas PD, Vrijens B, Eastell R et al (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296-1304
21. Nielsen D, Ryg J, Nielsen W, Knold B, Nissen N, Brixen K (2010) Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial. Patient Educ Couns 81:155-160
22. Ojeda-Bruno S, Naranjo A, Francisco-Hernandez F et al (2011) Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates. Osteoporos Int 22:1821-1828
23. Robbins B, Rausch KJ, Garcia RI, Prestwood KM (2004) Multicultural medication adherence: a comparative study. J Gerontol Nurs 30:25-32
24. Shu AD, Stedman MR, Polinski JM et al (2009) Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care 15:417-424
25. Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896-905
26. Freemantle N, Satram-Hoang S, Tang ET et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317-326
27. Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X (2006) Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int 17:664-671
28. Heilmann RM, Friesleben CR, Billups SJ (2012) Impact of a pharmacist-directed intervention in postmenopausal women after fracture. Am J Health Syst Pharm 69:504-509
29. Hill DA, Cacciatore M, Lamvu GM (2010) Electronic prescribing influence on calcium supplementation: a randomized controlled trial. Am J Obstet Gynecol 202(236):e1-e5
30. Kendler DL, McClung MR, Freemantle N et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725-1735
31. Lai PS, Chua SS, Chew YY, Chan SP (2011) Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. J Clin Pharm Ther 36:557-567
32. Montori VM, Shah ND, Pencille LJ et al (2011) Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med 124:549-556
33. Roux C, Giraudeau B, Rouanet S, Dubourg G, Perrodeau E, Ravaud P (2011) Monitoring of bone turnover markers does not improve persistence with ibandronate treatment. Joint Bone Spine 79:389-392
34. Silverman SL, Nasser K, Nattrass S, Drinkwater B (2012) Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial. Osteoporos Int 23:1069-1074
35. Solomon DH, Iversen MD, Avorn J et al (2012) Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med 172:477-483
36. Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT (2010) Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int 21:391-398
37. Gwadry-Sridhar FH, Manias E, Zhang Y et al (2009) A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther 31:421-435
38. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10:3-12
39. Vrijens B, De Geest S, Hughes DA et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691-705